Search results for PD-L1

APC Anti-PD-L1 antibody [10F.9G2], Abcam, AB272329

APC Anti-PD-L1 antibody [28-8], Abcam, AB206967

Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .

FITC Anti-PD-L1 antibody [28-8], Abcam, AB224027

Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .

Anti-PD-L1 antibody [SP142] - C-terminal, Abcam, AB228462

Anti-PD-L1 antibody [SP142] - C-terminal (ab228462) was developed by Abcam using patented rabbit monoclonal antibody technology and is validated for use in ICC/IF, IHC-P and mIHC. Anti-PD-L1 antibody [SP142] - C-terminal (ab228462) was first used in a scientific publication in 2016 and has been cited over 95 times in peer reviewed journals. It's performance in IHC in human and mouse samples is trusted by the scientific community. Abcam's high quality manufacturing and validation processes ensure Anti-PD-L1 antibody [SP142] - C-terminal (ab228462) has high sensitivity and specificity alongside high lot-to-lot consistency and reproducibility. Anti-PD-L1 antibody [SP142] - C-terminal (ab228462) specifically detects PD-L1 (UniProt ID: Q9NZQ7; Molecular weight: 32kDa) and is sold in a convenient trial size to enable initial testing (20 µL) and larger sizes for subsequent scaling up experiments (100 µL, 500 µL and 1 mL). Conjugation-ready, carrier free format available for antibody clone SP142 - ab236238 . Antibody clone SP142 is also available pre-conjugated to a variety of labels for your convenience - Alexa Fluor ® 647, Alexa Fluor ® 488, Alexa Fluor ® 594, Alexa Fluor ® 568, Alexa Fluor ® 555, Alexa Fluor ® 750 ( ab267563 , ab310995 , ab311750 , ab313030 , ab313231 , ab321463 ). Anti-PD-L1 antibody [SP142] - C-terminal (ab228462) is a clone from the portfolio of Spring Bioscience (Roche) SP clones which have been optimised for immunohistochemistry (IHC). PD-L1 allows tumors to escape immune detection by binding to the PD-1 receptor on T-cells, suppressing their function. Blocking this interaction with immune checkpoint inhibitors reactivates T-cells, enabling them to attack cancer cells. Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .

HRP Anti-PD-L1 antibody [28-8], Abcam, AB209961

Anti-PD-L1 antibody [28-8] has been used as detector antibody in Human PD-L1 SimpleStep ELISA® kit ( ab214565 ) . Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents .

PE Rabbit anti-Human PD-L1/CD274 mAb, ABclonal, A26692

Anti-CD274/PD-L1/B7-H1 Antibody (R3X08), AntibodySystem, RHJ70111

Anti-CD274/PD-L1/B7-H1 Antibody (R3X09), AntibodySystem, RHJ70110

Anti-CD274/PD-L1/B7-H1 Antibody (R4E26), AntibodySystem, RHJ70112

Biotin Anti-PD-L1 antibody [28-8] (Detector), Abcam, AB322788

How are conjugated primary antibodies validated? This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling. For suitable applications and species reactivity, please refer to the unconjugated version of this clone. Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .